Scarica l'app Stockscreener
3.80
6.60%
-0.2685
Precedente Chiudi:
$4.0685
Aprire:
$4.0043
Volume 24 ore:
4,867
Relative Volume:
0.55
Capitalizzazione di mercato:
$192.87M
Reddito:
$27,600
Utile/perdita netta:
$-36.04M
Rapporto P/E:
-2.1442
EPS:
-1.7722
Flusso di cassa netto:
$-1.66M
1 W Prestazione:
-6.17%
1M Prestazione:
-21.00%
6M Prestazione:
-46.55%
1 anno Prestazione:
-36.67%
Intervallo 1D:
$3.77
$4.0043
Intervallo di 1 settimana:
$3.5733
$4.2036
Portata 52W:
$3.5733
$8.962
Nanobiotix Adr Stock (NBTX) Company Profile
Confronta NBTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NBTX | 3.795 | 192.87M | 27,600 | -36.04M | -1.66M | -1.7722 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.98 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-06 | Iniziato | Evercore ISI | Outperform |
Nanobiotix Adr Borsa (NBTX) Ultime notizie
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat
Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail
Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks
Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks
Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer StudyTipRanks.com - TipRanks
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks
Nanobiotix Sa ADR Updates Share Capital InfoTipRanks.com - TipRanks
Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 - The Globe and Mail
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC ... - The Globe and Mail
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive ... - The Globe and Mail
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Nanobiotix Adr Azioni (NBTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):